1
|
Crocoli A, Martucci C, Persano G, De Pasquale MD, Serra A, Accinni A, Aloi IP, Bertocchini A, Frediani S, Madafferi S, Pardi V, Inserra A. Vascular Access in Pediatric Oncology and Hematology: State of the Art. CHILDREN 2022; 9:children9010070. [PMID: 35053694 PMCID: PMC8774620 DOI: 10.3390/children9010070] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 11/28/2021] [Revised: 12/15/2021] [Accepted: 12/30/2021] [Indexed: 12/27/2022]
Abstract
Management and successful use of vascular access are critical issues in pediatric patients affected by malignancies. Prolonged course of disease, complex and various treatment protocols require long-lasting vascular access providing adequate tools to administrate those therapies and to collect routine blood sampling without painful and repeated venipuncture. For these reasons, central venous catheters are currently an important component in pediatric onco-hematological care, with a direct influence on outcome. Indeed, there are peculiar issues (techniques of insertion, management, complications etc.) which must be well-known in order to improve the outcome and the quality of life of children with cancer.
Collapse
Affiliation(s)
- Alessandro Crocoli
- General Surgery Department, Bambino Gesu Children’s Hospital, IRCCS, 00165 Rome, Italy; (A.C.); (G.P.); (A.A.); (I.P.A.); (A.B.); (S.F.); (S.M.); (V.P.); (A.I.)
| | - Cristina Martucci
- General Surgery Department, Bambino Gesu Children’s Hospital, IRCCS, 00165 Rome, Italy; (A.C.); (G.P.); (A.A.); (I.P.A.); (A.B.); (S.F.); (S.M.); (V.P.); (A.I.)
- Correspondence: ; Tel.: +39-0668592155
| | - Giorgio Persano
- General Surgery Department, Bambino Gesu Children’s Hospital, IRCCS, 00165 Rome, Italy; (A.C.); (G.P.); (A.A.); (I.P.A.); (A.B.); (S.F.); (S.M.); (V.P.); (A.I.)
| | - Maria Debora De Pasquale
- Paediatric Haematology/Oncology Cell and Gene Therapy Department, Bambino Gesu Children’s Hospital, IRCCS, 00165 Rome, Italy; (M.D.D.P.); (A.S.)
| | - Annalisa Serra
- Paediatric Haematology/Oncology Cell and Gene Therapy Department, Bambino Gesu Children’s Hospital, IRCCS, 00165 Rome, Italy; (M.D.D.P.); (A.S.)
| | - Antonella Accinni
- General Surgery Department, Bambino Gesu Children’s Hospital, IRCCS, 00165 Rome, Italy; (A.C.); (G.P.); (A.A.); (I.P.A.); (A.B.); (S.F.); (S.M.); (V.P.); (A.I.)
| | - Ivan Pietro Aloi
- General Surgery Department, Bambino Gesu Children’s Hospital, IRCCS, 00165 Rome, Italy; (A.C.); (G.P.); (A.A.); (I.P.A.); (A.B.); (S.F.); (S.M.); (V.P.); (A.I.)
| | - Arianna Bertocchini
- General Surgery Department, Bambino Gesu Children’s Hospital, IRCCS, 00165 Rome, Italy; (A.C.); (G.P.); (A.A.); (I.P.A.); (A.B.); (S.F.); (S.M.); (V.P.); (A.I.)
| | - Simone Frediani
- General Surgery Department, Bambino Gesu Children’s Hospital, IRCCS, 00165 Rome, Italy; (A.C.); (G.P.); (A.A.); (I.P.A.); (A.B.); (S.F.); (S.M.); (V.P.); (A.I.)
| | - Silvia Madafferi
- General Surgery Department, Bambino Gesu Children’s Hospital, IRCCS, 00165 Rome, Italy; (A.C.); (G.P.); (A.A.); (I.P.A.); (A.B.); (S.F.); (S.M.); (V.P.); (A.I.)
| | - Valerio Pardi
- General Surgery Department, Bambino Gesu Children’s Hospital, IRCCS, 00165 Rome, Italy; (A.C.); (G.P.); (A.A.); (I.P.A.); (A.B.); (S.F.); (S.M.); (V.P.); (A.I.)
| | - Alessandro Inserra
- General Surgery Department, Bambino Gesu Children’s Hospital, IRCCS, 00165 Rome, Italy; (A.C.); (G.P.); (A.A.); (I.P.A.); (A.B.); (S.F.); (S.M.); (V.P.); (A.I.)
| |
Collapse
|
2
|
Karalexi MA, Pourtsidis A, Panagopoulou P, Moschovi M, Polychronopoulou S, Kourti M, Hatzipantelis E, Stiakaki E, Dana H, Bouka P, Ntzani EE, Petridou ET. Overall and event-free survival of childhood lymphoma in Greece: analysis of harmonized clinical data over a 24-year active registration period. Leuk Lymphoma 2021; 62:2107-2119. [PMID: 34114936 DOI: 10.1080/10428194.2021.1907376] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
We assessed event-free (EFS) and overall (OS) survival in 676 incident cases of childhood Hodgkin (HL) and non-Hodgkin (NHL) lymphoma actively registered in Greece (1996-2019). HL-OS5-year was 96% and NHL-OS5-year 85%, whereas HL-EFS5-year was 86% and NHL-EFS5-year was 81%, notably similar to the respective OS rates (HL: 95%, NHL: 85%) in developed countries. For HL, older age at diagnosis, high maternal education and close proximity to treatment centers were linked to remarkably favorable outcomes. By contrast, stage IV patients showed worse OS and EFS. HL patients with low levels of hemoglobin were associated with worse EFS (hazard ratio: 2.81, 95% confidence intervals: 1.09-7.22). OS (76%) and EFS (73%) were poor among high-risk NHL patients and those with increased LDH (71%). The identified predictors of poor disease outcome point to the need for intensification of individualized treatments. Ongoing clinical cancer registration entailing clinical components could contribute to use of state-of-the-art treatments.
Collapse
Affiliation(s)
- Maria A Karalexi
- Department of Hygiene, Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, Athens, Greece.,Hellenic Society for Social Pediatrics and Health Promotion, Athens, Greece
| | - Apostolos Pourtsidis
- Department of Pediatric Hematology-Oncology, "P&A Kyriakou" Children's Hospital, Athens, Greece
| | | | - Maria Moschovi
- Pediatric Hematology/Oncology Unit, First Department of Pediatrics, National and Kapodistrian University of Athens, "Agia Sofia" Children's Hospital, Athens, Greece
| | - Sophia Polychronopoulou
- Department of Pediatric Hematology-Oncology, "Agia Sofia" Children's Hospital, Athens, Greece
| | - Maria Kourti
- Department of Pediatric Hematology and Oncology, Hippokration Hospital, Thessaloniki, Greece
| | - Emmanuel Hatzipantelis
- Hematology-Oncology Unit, 2nd Pediatric Department, Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece
| | - Eftichia Stiakaki
- Department of Pediatric Hematology-Oncology, University of Crete, Heraklion, Greece
| | - Helen Dana
- Pediatric Hematology-Oncology Department, "Mitera" Children's Hospital, Athens, Greece
| | | | - Panagiota Bouka
- Hellenic Society for Social Pediatrics and Health Promotion, Athens, Greece
| | - Evangelia E Ntzani
- Department of Hygiene and Epidemiology, School of Medicine, University of Ioannina, Ioannina, Greece.,Center for Evidence Synthesis in Health, Brown University School of Public Health, Providence, RI, USA
| | - Eleni Th Petridou
- Department of Hygiene, Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, Athens, Greece.,Hellenic Society for Social Pediatrics and Health Promotion, Athens, Greece
| |
Collapse
|
3
|
Hess CB, Parkes J, Janssens GO, Lin C, Wong K, Zaghloul MS, Marconi DG, Boterberg T, Esiashvili N. Global pediatric radiation therapy in resource-limited settings. Pediatr Blood Cancer 2021; 68 Suppl 2:e28299. [PMID: 32743983 DOI: 10.1002/pbc.28299] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/25/2020] [Accepted: 03/10/2020] [Indexed: 12/24/2022]
Abstract
This report provides a summary of the global burden of childhood cancer morbidity and mortality, which disproportionately affects low- and middle-income countries as well as low- and middle-income communities within high-income countries. We review past successes and current challenges to improving clinical pediatric radiotherapy, education, and research in these regions. The Pediatric Radiation Oncology Society Taskforce in Low- and Middle-Income Countries recently outlined specific aims: (a) to increase access and quality of radiotherapy for children and adolescents afflicted with cancer; (b) to enumerate, engage, and educate a global community of providers of childhood and adolescent radiotherapy; and (c) to create evidence establishing the outcomes of setting-specific treatment standards of care when first-world standards are not achievable. This report will improve awareness of these disparities and promote attempts to correct them.
Collapse
Affiliation(s)
- Clayton B Hess
- Department of Radiation Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia.,Department of Radiation Oncology, Massachusetts General Hospital, Harvard University, Boston, Massachusetts
| | - Jeannette Parkes
- Department of Radiation Oncology, Groote Schuur Hospital, University of Cape Town, Cape Town, South Africa
| | - Geert O Janssens
- Department of Radiation Oncology, Ghent University Hospital, Ghent, Belgium
| | - Chi Lin
- Department of Radiation Oncology, University of Nebraska Medical Center, University of Nebraska, Omaha, Nebraska
| | - Kenneth Wong
- Department of Radiation Oncology, Children's Hospital Los Angeles, University of Southern California, Los Angeles, California
| | - Mohamed S Zaghloul
- Children's Cancer Hospital, National Cancer Institute, Cairo University, Cairo, Egypt
| | - Daniel G Marconi
- Department of Radiation Oncology, Barretos Cancer Hospital, Barretos, São Paulo, Brazil
| | - Tom Boterberg
- Department of Radiation Oncology, Ghent University Hospital, Ghent, Belgium
| | - Natia Esiashvili
- Department of Radiation Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia
| |
Collapse
|
4
|
Rodriguez-Pla A, Simms RW. Geographic disparity in systemic sclerosis mortality in the United States: 1999–2017. JOURNAL OF SCLERODERMA AND RELATED DISORDERS 2019; 6:139-145. [DOI: 10.1177/2397198319869566] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2019] [Accepted: 07/06/2019] [Indexed: 11/15/2022]
Abstract
Introduction: Previous studies reported a progressive decrease in the systemic sclerosis mortality rates in the United States from 1959 to 2002. Identification of areas with clusters of higher mortality rates is important to implement targeted interventions. In this study, we aimed to estimate the mortality rates of scleroderma and to analyze its geographic variability at the state level in the United States. Methods: Mortality rates of scleroderma from 1999 to 2017 were obtained from the CDC Wonder Underlying Cause of Death database and its query system, using International Classification of Diseases, Tenth Revision codes. Age-adjusted rates were calculated by state and demographics. A linear regression model was applied to evaluate trends over time. Results: Over the period studied, a total of 24,525 deaths had scleroderma as the underlying cause of death. The age-adjusted mortality rate was 3.962 per million (95% CI: 3.912–4.012), decreasing progressively from 4.679 (95%CI: 4.423–4.934) in 1999 to 2.993 (95% CI: 2.817–3.170) per million in 2017. The age-adjusted mortality rate was 5.885 (95% CI: 5.802–5.967) and 1.651 (95% CI: 1.604–1.698) per million in females and males, respectively. Per races, the highest age-adjusted mortality rate was in Blacks or African Americans, at 5.703 per million (95% CI: 5.521–5.885), followed by American Indians or Alaska Native at 5.047 per million (95% CI: 4.428–5.667). Clusters of states with higher and lower mortality rates were identified. South Dakota had the highest whereas Hawaii had the lowest mortality rate. Conclusion: We found a trend to a progressive decrease in mortality rates of scleroderma during the years of our study. In addition, we found relevant state-by-state variation in mortality with several geographical clusters with higher mortality rates. Further analyses are warranted in order to better understand the factors associated with the observed geographic disparities.
Collapse
Affiliation(s)
- Alicia Rodriguez-Pla
- Division of Rheumatology, The University of Arizona, Tucson, AZ, USA
- Banner University Medical Center Tucson, Tucson, AZ, USA
| | - Robert W Simms
- Division of Rheumatology, Boston University, Boston, MA, USA
| |
Collapse
|
5
|
Janssens GO, Timmermann B, Laprie A, Mandeville H, Padovani L, Chargari C, Journy N, Kameric L, Kienesberger A, Brunhofer M, Kozhaeva O, Gasparotto C, Kearns P, Boterberg T, Lievens Y, Vassal G. Recommendations for the organisation of care in paediatric radiation oncology across Europe: a SIOPE-ESTRO-PROS-CCI-Europe collaborative project in the framework of the JARC. Eur J Cancer 2019; 114:47-54. [PMID: 31059973 DOI: 10.1016/j.ejca.2019.03.003] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2019] [Accepted: 03/04/2019] [Indexed: 12/17/2022]
Abstract
Disparities in survival and long-term side-effects from paediatric cancer are observed across European Society for Paediatric Oncology (SIOPE)-affiliated countries. The Joint Action on Rare Cancers (JARC) is a project supported by the European Union and member states aiming to formulate recommendations on rare cancers, including paediatric malignancies, to reduce inequalities and to improve health outcomes. Most paediatric cancers are treated by a combination of systemic agents, surgery and/or radiotherapy. Radiotherapy for children is becoming increasingly complex because of the growing availability of new modalities and techniques and the evolution in molecular biology. These added challenges have the potential to enhance disparities in survival and side-effects between countries, but also among centres in the same country. To tackle radiotherapy-related inequalities, representatives of SIOPE, European SocieTy for Radiotherapy and Oncology, Paediatric Radiation Oncology Society and Childhood Cancer International-Europe defined 'standard' and 'optional' levels to deliver Good Clinical Practice-compliant treatment in paediatric radiation oncology with a focus on patient-related care, education and training. In addition, more than 250 paediatric radiotherapy centres across the SIOPE-affiliated countries have been mapped. For a better understanding of resources in paediatric radiotherapy, JARC representatives are working on an online survey for paediatric radiation oncologists of each centre in SIOPE-affiliated countries. The outcome of this survey will give an insight into the strengths and weaknesses of paediatric radiotherapy across SIOPE-affiliated countries and can be relevant for European Reference Networks in terms of collaboration pathways and referrals in paediatric radiotherapy.
Collapse
Affiliation(s)
- Geert O Janssens
- Department of Radiation Oncology, University Medical Centre Utrecht, the Netherlands; Princess Maxima Centre for Paediatric Oncology, Utrecht, the Netherlands.
| | - Beate Timmermann
- Department of Particle Therapy, University Hospital Essen, West German Proton Therapy Centre Essen (WPE), West German Cancer Centre (WTZ), German Cancer Consortium (DKTK), Germany
| | - Anne Laprie
- Department of Radiation Oncology, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France; Toulouse NeuroImaging Center, ToNIC, INSERM Université Toulouse III Paul Sabatier, Toulouse, France
| | - Henry Mandeville
- Department of Radiotherapy, The Royal Marsden Hospital, Sutton, United Kingdom
| | - Laetitia Padovani
- Department of Radiation Oncology, CRCM, UMR 1068 Inserm 7258 CNRS, Assistance Publique Hôpitaux de Marseille, Marseille, France
| | - Cyrus Chargari
- Department of Radiation Oncology, Gustave Roussy, Villejuif, France
| | - Neige Journy
- INSERM Unit 1018, Centre for Research in Epidemiology and Population Health (CESP), Cancer and Radiations Group, Gustave Roussy, Villejuif, France
| | - Lejla Kameric
- Childhood Cancer International - Europe, Vienna, Austria
| | | | | | - Olga Kozhaeva
- European Society for Paediatric Oncology (SIOP Europe), Brussels, Belgium
| | - Chiara Gasparotto
- European Society for Radiotherapy & Oncology (ESTRO), Brussels, Belgium
| | - Pamela Kearns
- European Society for Paediatric Oncology (SIOP Europe), Brussels, Belgium; European Society for Radiotherapy & Oncology (ESTRO), Brussels, Belgium; Institute of Cancer and Genomic Sciences, NIHR Birmingham Biomedical Research Centre, University of Birmingham, Birmingham, United Kingdom
| | - Tom Boterberg
- Department of Radiation Oncology, Ghent University Hospital, Ghent, Belgium
| | - Yolande Lievens
- European Society for Radiotherapy & Oncology (ESTRO), Brussels, Belgium; Institute of Cancer and Genomic Sciences, NIHR Birmingham Biomedical Research Centre, University of Birmingham, Birmingham, United Kingdom; Department of Radiation Oncology, Ghent University Hospital, Ghent, Belgium
| | - Gilles Vassal
- European Society for Paediatric Oncology (SIOP Europe), Brussels, Belgium; Department of Clinical Research, Gustave Roussy, Paris-Sud University, Paris, France
| |
Collapse
|
6
|
Choeyprasert W, Anurathapan U, Pakakasama S, Sirachainan N, Songdej D, Lertthammakiat S, Hongeng S. Pediatric non-Hodgkin lymphoma: Characteristics, stratification, and treatment at a single institute in Thailand. Pediatr Int 2019; 61:49-57. [PMID: 30734424 DOI: 10.1111/ped.13739] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/02/2018] [Revised: 07/21/2018] [Accepted: 09/04/2018] [Indexed: 12/12/2022]
Abstract
BACKGROUND In the modern era of chemotherapy, the outcome of pediatric non-Hodgkin lymphoma (NHL) continues to improve internationally. Limited data such as information on epidemiology and survival, however, are available in Asian countries. METHODS Children (≤15 years old) diagnosed with histologically proven NHL from 1998 to 2014 were retrospectively analyzed. RESULTS In total, 114 patients were enrolled; they were predominantly male (65.8%) and had advanced disease (stage III, IV; 71.9%). Of these, 22.8% had Burkitt lymphoma, 20.2% had diffuse large B-cell lymphoma, 21.1% had lymphoblastic lymphoma, 20.2% had large cell lymphoma, and 15.8% had peripheral T-cell lymphoma. Twenty-nine patients died, especially of uncontrolled disease (62.1%) and infection (20.7%). During a median follow up of 78.4 months, Kaplan-Meier 5 year event-free and overall survival rates were 71.5% ± 4.3% and 74.8% ± 4.1%, respectively, regardless of subtype. B symptoms (i.e. systemic symptoms of fever, night sweats, and weight loss that can be associated with both Hodgkin's lymphoma and non-Hodgkin's lymphoma) and advanced disease had a significant negative impact on 5 year survival. No other prognostic factor was found, but survival tended to have a negative correlation with age. CONCLUSIONS Pediatric NHL is aggressive, with a high prevalence of peripheral T-cell lymphoma. The present treatment stratification seems to be effective compared with that used in developed countries.
Collapse
Affiliation(s)
- Worawut Choeyprasert
- Department of Pediatrics, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
| | - Usanarat Anurathapan
- Department of Pediatrics, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
| | - Samart Pakakasama
- Department of Pediatrics, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
| | - Nongnuch Sirachainan
- Department of Pediatrics, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
| | - Duantida Songdej
- Department of Pediatrics, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
| | - Surapong Lertthammakiat
- Department of Pediatrics, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
| | - Suradej Hongeng
- Department of Pediatrics, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
| |
Collapse
|
7
|
Sorge C, Costa LJ, Taub JW, S. Cairo M, Xavier AC. Incidence and outcomes of rare paediatric non-hodgkin lymphomas. Br J Haematol 2018; 184:864-867. [DOI: 10.1111/bjh.15194] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Affiliation(s)
- Caryn Sorge
- Division of Hematology/Oncology; Department of Pediatrics; University of Kentucky; Lexington KY USA
| | - Luciano J. Costa
- Division of Hematology/Oncology; Department of Medicine; University of Alabama at Birmingham; Birmingham AL USA
| | - Jeffrey W. Taub
- Division of Hematology/Oncology; Department of Pediatrics; Children's Hospital of Michigan/Wayne State University; Detroit MI USA
| | - Mitchell S. Cairo
- Departments of Pediatrics, Pathology, Medicine, Immunology and Microbiology; Cell Biology and Anatomy; New York Medical College; Valhalla NY USA
| | - Ana C. Xavier
- Division of Hematology/Oncology; Department of Pediatrics; Children's of Alabama/University of Alabama at Birmingham; Birmingham AL USA
| |
Collapse
|
8
|
Georgakis MK, Papathoma P, Ryzhov A, Zivkovic-Perisic S, Eser S, Taraszkiewicz Ł, Sekerija M, Žagar T, Antunes L, Zborovskaya A, Bastos J, Florea M, Coza D, Demetriou A, Agius D, Strahinja RM, Themistocleous M, Tolia M, Tzanis S, Alexiou GA, Papanikolaou PG, Nomikos P, Kantzanou M, Dessypris N, Pourtsidis A, Petridou ET. Malignant central nervous system tumors among adolescents and young adults (15-39 years old) in 14 Southern-Eastern European registries and the US Surveillance, Epidemiology, and End Results program: Mortality and survival patterns. Cancer 2017; 123:4458-4471. [DOI: 10.1002/cncr.30884] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2017] [Revised: 06/09/2017] [Accepted: 06/23/2017] [Indexed: 11/11/2022]
Affiliation(s)
- Marios K. Georgakis
- Department of Hygiene, Epidemiology, and Medical Statistics, School of Medicine; National and Kapodistrian University of Athens; Athens Greece
| | - Paraskevi Papathoma
- Department of Hygiene, Epidemiology, and Medical Statistics, School of Medicine; National and Kapodistrian University of Athens; Athens Greece
- Department of Neurology; University Hospital; Linköping Sweden
| | - Anton Ryzhov
- National Cancer Registry of Ukraine; National Institute of Cancer; Kiev Ukraine
| | | | - Sultan Eser
- Izmir Cancer Registry, Izmir Hub; Izmir and Hacettepe University Institute of Public Health; Ankara Turkey
| | - Łukasz Taraszkiewicz
- Greater Poland Cancer Registry, Department of Cancer Prevention and Epidemiology; Greater Poland Cancer Center; Poznan Poland
| | - Mario Sekerija
- Croatian National Cancer Registry; Croatian Institute of Public Health; Zagreb Croatia
| | - Tina Žagar
- Cancer Registry of the Republic of Slovenia; Institute of Oncology; Ljubljana Slovenia
| | - Luis Antunes
- North Region Cancer Registry of Portugal; Portuguese Oncology Institute of Porto; Porto Portugal
| | - Anna Zborovskaya
- Belarusian Research Center for Pediatric Oncology, Hematology, and Immunology; Childhood Cancer Subregistry of Belarus; Minsk Belarus
| | - Joana Bastos
- Central Region Cancer Registry of Portugal; Portuguese Oncology Institute of Coimbra; Coimbra Portugal
| | - Margareta Florea
- Regional Cancer Registry of Iasi; National Institute of Public Health; Iasi Romania
| | - Daniela Coza
- Regional Cancer Registry of Cluj; Ion Chiricuta Oncological Institute; Cluj-Napoca Romania
| | - Anna Demetriou
- Cyprus Cancer Registry, Health Monitoring Unit; Ministry of Health; Nicosia Cyprus
| | - Domenic Agius
- Malta National Cancer Registry, Department of Health Information and Research; Valletta Malta
| | - Rajko M. Strahinja
- Cancer Registry, Department for Epidemiology of Noncommunicable Diseases, Center for Disease Prevention and Control; Institute of Public Health; Podgorica Montenegro
| | | | - Maria Tolia
- Second Department of Radiology, Radiotherapy Unit, Attikon University Hospital, School of Medicine; National and Kapodistrian University of Athens; Greece Athens
| | - Spyridon Tzanis
- Neurosurgery Department; Errikos Dunant Hospital Center; Athens Greece
| | - George A. Alexiou
- Neurosurgical Institute; Ioannina University School of Medicine; Ioannina Greece
| | | | - Panagiotis Nomikos
- Department of Neurosurgery and Gamma Knife Radiosurgery; Hygeia Hospital; Athens Greece
| | - Maria Kantzanou
- Department of Hygiene, Epidemiology, and Medical Statistics, School of Medicine; National and Kapodistrian University of Athens; Athens Greece
| | - Nick Dessypris
- Department of Hygiene, Epidemiology, and Medical Statistics, School of Medicine; National and Kapodistrian University of Athens; Athens Greece
| | - Apostolos Pourtsidis
- Department of Pediatric Hematology and Oncology; Panagiotis and Aglaia Kyriakou Children's Hospital; Athens Greece
| | - Eleni T. Petridou
- Department of Hygiene, Epidemiology, and Medical Statistics, School of Medicine; National and Kapodistrian University of Athens; Athens Greece
- Clinical Epidemiology Unit, Department of Medicine; Karolinska Institute; Stockholm Sweden
| |
Collapse
|